Atrion (ATRI) Hits New 1-Year High at $796.00

Atrion Co. (NASDAQ:ATRI) reached a new 52-week high on Thursday . The company traded as high as $796.00 and last traded at $792.57, with a volume of 76 shares traded. The stock had previously closed at $785.70.

Separately, BidaskClub lowered shares of Atrion from a “strong-buy” rating to a “buy” rating in a report on Tuesday.

The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of 41.62 and a beta of 0.57.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 17th. Investors of record on Monday, December 3rd will be issued a $1.35 dividend. The ex-dividend date of this dividend is Friday, November 30th. This represents a $5.40 dividend on an annualized basis and a dividend yield of 0.70%.

In related news, CFO Jeffery Strickland sold 2,000 shares of the company’s stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $768.07, for a total value of $1,536,140.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 22.46% of the company’s stock.

A number of large investors have recently bought and sold shares of ATRI. Cornerstone Wealth Management LLC increased its stake in Atrion by 21.6% in the 3rd quarter. Cornerstone Wealth Management LLC now owns 65,995 shares of the medical instruments supplier’s stock valued at $100,000 after buying an additional 11,743 shares during the last quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new stake in Atrion in the 2nd quarter valued at about $240,000. Waldron Private Wealth LLC purchased a new stake in Atrion in the 3rd quarter valued at about $240,000. Principal Financial Group Inc. purchased a new stake in Atrion in the 1st quarter valued at about $249,000. Finally, Chevy Chase Trust Holdings Inc. purchased a new stake in Atrion in the 2nd quarter valued at about $300,000. Hedge funds and other institutional investors own 63.56% of the company’s stock.

WARNING: This report was posted by WKRB News and is the property of of WKRB News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at

Atrion Company Profile (NASDAQ:ATRI)

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

See Also: Book Value Per Share in Stock Trading

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with's FREE daily email newsletter.

Leave a Reply